References
- 1. Bishop J. R., Schuksz M., Esko J.D.: Heparan sulphate proteoglycans fine-tune mammalian in physiology. Nature, 446, 1030, 2007.
- 2. Dallinga G.M. et al.: The metabolism of triglyceride-rich lipoproteins revisited: New players, new insight. Atherosclerosis, 211, 1-8, 2010.
- 3. De Muro P. et al.: Urinary glycosaminoglycans composition in chronic glomerulonephritis. J Nephrol., 18, 154-160, 2005.
- 4. Fogelstrand P., Boren J.: Retention of atherogenic lipoproteins in the artery wall and its role in atherogenesis. Nutrition, metabolism & Cardiovascular Diseases, 22, 1-7, 2012.
- 5. Hosono-Fukao T. et al.: Heparan Sulfate subdomains that are degraded by sulf accumulate in cerebral amyloid β plaques of Alzheimer’s disease. Am J Pathol., 180, 2056-2067, 2012.
- 6. Jefferson A., Shankland S.J., Pichler R.H.: Proteinuria in diabetic kidney disease: A mechanistic viewpoint. Kidney International, 74, 22-36, 2008.
- 7. Ki rn-Saf ran C., Farach-Carson M.C., Carson D. D.: Multifunctionality of extracellular and cell surface heparan sulfate proteoglycans. Cell. Mol. Life Sci., 66, 3421-3434, 2009.
- 8. Kolset S.O., Salmivirta M.: Cell surface heparan sulfate proteoglycans and lipoprotein metabolism. Cellular and molecular life sciences, 56, 857, 1999.
- 9. Lahdesmaki K. et al.: Acidity and lipolysis by group V secreted phospholipase A(2) strongly increase the binding of apoB-100- containing lipoproteins to human aortic proteoglycans. Biochim Biophys Acta, 1821, 257, 2012.
- 10. Madonna R., De Caterina R.: Potential roles of vessel wall heparan sulfate proteoglycans in atherosclerosis. Vascular Pharmacology, 62, 3, 120-122, 2014.
- 11. Malavaki Ch. J. et al.: Heparan sulfate: biological significance, tools for biochemical analysis and structural characterization. Biomed. Chromatogr., 25, 11, 2011.
- 12. Miner J. H.: The Glomerular Basement Membrane. Exp Cell Res., 318(9): 973-978, 2012.
- 13. Nakashima Y., Wight T.N., Sueishi K.: Early atheroslcerosis in humas: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovascular research, 79, 14, 2008.
- 14. Reitsma S. et al.: The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch-Eur J Phisiol, 454, 345-359, 2007.
- 15. Sarrazin S., Lamanna W. C., Esko J.D.: Heparan Sulfate Proteoglycans. Cold Spring Harb Perspect Biol., 3;a004952, 2011.
- 16. Segev A., Nili N., Strauss B.H.: The role of perlecan in arterial injury and angiogenesis. Cardiovascular Research, 63, 603, 2004.
- 17. Swarup V. P. et al.: Sugar glues for broken neurons. BiolMolecular Concepts, 4, 3, 233-257, 2013.
- 18. Tannock L. R., King V. L.: Proteoglycan mediated lipoprotein retention: A mechanism of diabetic atherosclerosis. Reviews in Endocrine & Metabolic Disorders, 9, 289, 2008.
- 19. Tarbell J. M. Tarbell: Shear stress and the endothelial transport barrier, Cardiovasc Res., 87, 320, 2010.
- 20. van den Berg B. M., Spaan J. A., Vink H.: Impaired glycocalyx barrier properties contribute to enhanced intimal low-density lipoprotein accumulation at the caroid artery bifurcation in mice. Pflugers Arch - Eur J Physil., 457: 1199-1206, 2009.
- 21. Zaferani A. et al.: Heparin/heparan sulphate interactions with complement - a possible target for reduction of renal function loss? Nephrol Dial Transplant, 0: 1-9, 2013.